Mellissa Holt, ADT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 5710 Ritchie Hwy, Brooklyn Park, MD 21225 Phone: 410-636-5600 |
Alexis Marie Roberson, LCPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 216 E Cedar Hill Ln, Brooklyn Park, MD 21225 Phone: 412-979-2554 |
Kimberly Taylor, ADT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 5710 Ritchie Hwy, Brooklyn Park, MD 21225 Phone: 410-636-5600 |
Elizabeth Walters, ADT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 5710 Ritchie Hwy, Brooklyn Park, MD 21225 Phone: 410-636-5600 |
Mrs. Kathyann P Wilson-beauford Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 5710 Ritchie Hwy, Brooklyn Park, MD 21225 Phone: 410-636-5600 Fax: 410-636-5600 |
News Archive
A new study by researchers at the UC Davis MIND Institute suggests that women who consume the recommended daily dosage of folic acid, the synthetic form of folate or vitamin B-9, during the first month of pregnancy may have a reduced risk of having a child with autism.
A global alliance of international organizations, including the heads of UNICEF, UNAIDS and The Global Fund to Fight AIDS, Tuberculosis and Malaria as well as other NGOs including the Pan African Treatment Access Movement, Health GAP, Ugandan Pediatric Association and the Global AIDS Alliance today agreed to take concerted action to eliminate pediatric HIV/AIDS over the next five years, preventing nearly 400,000 children annually from beginning their lives infected with the virus that causes AIDS.
President Barack Obama acknowledged to insurance executives that reinstating millions of insurance policies might cost them, according to Politico. Other media outlets report that brokers are worried about their role in the insurance marketplace and how one company is forecasting that a failure to enroll the uninsured could cut prescription drug sales by 30 percent in 2017.
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
› Verified 6 days ago